Table 3 Average cost per patient visit ( n = 244 )
From: Economic evaluation of task-shifting approaches to the dispensing of anti-retroviral therapy
| Â | Group A: full-time pharmacist | Group B: pharmacist assistant under indirect supervision | Group C: nurse-driven | |||
|---|---|---|---|---|---|---|
Pharm clinic 1 | Pharm clinic 2 | ISPA clinic 1 | ISPA clinic 2 | Nurse clinic 1 | Nurse clinic 2 | |
Average provider cost | Â | Â | Â | Â | Â | Â |
 Staff costs | US$6.08 | US$7.01 | US$5.09 | US$6.38 | US$11.19 | US$9.13 |
Total cost to provider per patient visit | US$6.08 | US$7.01 | US$5.09 | US$6.38 | US$11.19 | US$9.13 |
Average patient costs | Â | Â | Â | Â | Â | Â |
Direct costs | US$6.20 | US$3.35 | US$1.59 | US$1.65 | US$1.14 | US$3.00 |
Indirect costsa | US$5.42 | US$5.09 | US$7.47 | US$4.15 | US$3.60 | US$4.84 |
Total cost to patient per visit | US$11.62 | US$8.45 | US$9.06 | US$5.81 | U$4.74 | US$7.84 |
Total societal costs for ART care per visit | US$17.70 | US$15.46 | US$14.16 | US$12.19 | US$15.93 | US$16.97 |
Percentage of respondents who incurred direct costs, and found it unaffordable (n) | 90% (36) | 70% (14) | 77.78% (21) | 68% (17) | 64.29% (9) | 70.97% (22) |